Industry News
Gene deficiency in males 'could cause diabetes and liver cancer'
Dec 11, 2013
Scientists have discovered a genetic deficiency in males that could prompt the development of the most common type of liver cancer - hepatocellular carcinoma - and type 2 diabetes. This is according to a study published in the journal Cancer Cell. Read More
FoundationOne™ Heme enables identification of genomic alterations not identified by conventional methods across hematologic malignancies
Dec 11, 2013
Foundation Medicine has announced new data demonstrating that its fully informative genomic profile for hematologic cancers, FoundationOne™ Heme, can be performed in routine clinical cancer specimens to identify all classes of genomic alterations, including gene fusions, across hundreds of genes related to oncogenesis in patients with hematologic malignancies. Read More
Studies uncover new insights into pathophysiology of sickle cell disease and thalassemia, may help improve standard of care
Dec 11, 2013
New research presented during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncovers several important insights into the pathophysiology of sickle cell disease and thalassemia that may soon translate into the development of better, more targeted treatments for hundreds of thousands of patients worldwide. Read More
Experts cite new drug therapies as rationale for improvements in prostate cancer guidelines, coordination
Dec 11, 2013
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancer experts.In an article published online in the journal Urologic Oncology, urologist Ralph de Vere White and medical oncologist Primo Lara, Jr. Read More
Finding may lead to new prevention and treatment methods for prostate cancer
Dec 11, 2013
Doctors at the North Shore-LIJ Health System have discovered that increased inflammation in the prostate may predict reduced risk for prostate cancer. The findings are published online in CANCER.Prostate cancer is one of the most common cancers in men, with an estimated 240,000 new cases diagnosed every year - it kills approximately 30,000 men annually. Read More
Identification of 10-gene biomarker has implications for ovarian cancer discovery, survival outcomes
Dec 11, 2013
Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes. Read More
Initial consensus recommendations for studies of neurofibromatosis
Dec 11, 2013
As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches - including outcome measures specific to NF- are needed. Read More
Identification of 10-gene biomarker has implications for ovarian cancer discovery, survival outcomes
Dec 11, 2013
Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes. Read More
Researchers reveal potential biological factor contributing to racial disparities in prostate cancer
Dec 11, 2013
Researchers have uncovered a potential biological factor that may contribute to disparities in prostate cancer incidence and mortality between African-American and non-Hispanic white men in the United States, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Read More
Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib
Dec 11, 2013
In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions reported at the 2013 annual meeting of the American Society of Hematology (ASH). Read More
Previous Page Next Page